RAPT Therapeutics (NASDAQ:RAPT) Downgraded to Underweight Rating by JPMorgan Chase & Co.

JPMorgan Chase & Co. lowered shares of RAPT Therapeutics (NASDAQ:RAPT) from a neutral rating to an underweight rating in a research report sent to investors on Monday morning, Marketbeat Ratings reports.

Several other equities research analysts have also recently commented on the company. HC Wainwright reissued a “neutral” rating on shares of RAPT Therapeutics in a research note on Tuesday, August 20th. UBS Group decreased their target price on shares of RAPT Therapeutics from $10.00 to $2.00 and set a “neutral” rating for the company in a research report on Monday, September 9th. One analyst has rated the stock with a sell rating, ten have assigned a hold rating and two have given a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $13.00.

RAPT Therapeutics Trading Down 18.5 %

Shares of NASDAQ:RAPT opened at $1.28 on Monday. RAPT Therapeutics has a 1 year low of $1.25 and a 1 year high of $27.35. The business has a fifty day simple moving average of $1.96 and a 200 day simple moving average of $3.05.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Acadian Asset Management LLC bought a new position in RAPT Therapeutics during the first quarter worth $97,000. XTX Topco Ltd acquired a new position in shares of RAPT Therapeutics during the second quarter valued at about $108,000. Hennion & Walsh Asset Management Inc. raised its position in shares of RAPT Therapeutics by 8.6% during the second quarter. Hennion & Walsh Asset Management Inc. now owns 48,525 shares of the company’s stock valued at $148,000 after buying an additional 3,824 shares during the last quarter. EntryPoint Capital LLC acquired a new stake in RAPT Therapeutics during the first quarter worth about $161,000. Finally, Exchange Traded Concepts LLC grew its position in RAPT Therapeutics by 244.7% during the third quarter. Exchange Traded Concepts LLC now owns 89,076 shares of the company’s stock worth $179,000 after buying an additional 63,235 shares in the last quarter. 99.09% of the stock is currently owned by institutional investors and hedge funds.

RAPT Therapeutics Company Profile

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.